- Home
- XFOR vs RCKT Comparison
XFOR vs RCKT Comparison
Compare XFOR & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XFOR | RCKT |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.5M | 239.3M |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | XFOR | RCKT |
|---|---|---|
| Price | $3.15 | $2.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $11.60 | $8.58 |
| AVG Volume (30 Days) | 646.1K | ★ 2.0M |
| Earning Date | 11-04-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | N/A | ★ 0.66 |
| Revenue | ★ $6,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $915.60 |
| P/E Ratio | ★ N/A | $3.95 |
| Revenue Growth | ★ 150.00 | N/A |
| 52 Week Low | $2.43 | $2.17 |
| 52 Week High | $4.83 | $5.45 |
Technical Indicators
Market Signals| Indicator | XFOR | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 50.33 | 47.85 |
| Support Level | $2.83 | $2.17 |
| Resistance Level | $3.52 | $2.73 |
| Average True Range (ATR) | 0.26 | 0.18 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 53.47 | 64.00 |
Price Performance
Historical ComparisonAbout XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.